Zovegalisib

Laekna (HKEX: 02105) has licensed its pre-clinical PI3Kα inhibitor LAE118 to US-based Vasque Bio in a deal worth up to USD 527 million. Vasque will serve as a rare-disease-focused channel for the global development of Laekna’s next-generation mutant-selective kinase inhibitor, which has cleared IND review in both the US and China. The LAE118 license agreement, announced on June 9, 2026, grants Vasque Bio exclusive worldwide rights excluding Greater China to develop, manufacture, and commercialize the compound. The deal’s equity component — Laekna’s right to acquire up to a high-teen percentage of Vasque Bio stock at no additional cost — gives the originator direct exposure to any future exit. Under the terms, Laekna receives a USD 10 million non-refundable upfront payment, up to USD 517 million in combined development and sales milestones, and tiered royalties ranging from single-digit to double-digit percentages on any future net sales. A further clause entitles Laekna to up to 50% of the value of any qualifying strategic transaction — such as an acquisition or sublicense — that Vasque Bio enters involving LAE118. That provision is structurally uncommon and suggests Laekna negotiated aggressively to guard against a scenario where Vasque Bio exits cheaply before milestones are earned. Laekna’s PI3Kα inhibitor LAE118 is described by Laekna as a novel PI3Kα pan-mutant selective inhibitor, designed to target the mutant forms of the PI3Kα enzyme while sparing the wild-type protein. First-generation PI3Kα inhibitors, including Novartis’s alpelisib (Piqray/Vijoice), inhibit both mutant and wild-type enzyme, producing on-target toxicities — particularly hyperglycemia — that limit dosing and combination potential. Mutant-selective agents aim to widen the therapeutic window by concentrating activity on disease-driving variants. According to Laekna, LAE118 is being actively developed into clinical studies for PIK3CA-mutant solid tumors in both China and the US. The partnership introduces an unusual indication split. Laekna describes its own development focus as oncology, while Vasque Bio — backed by The Column Group and F-Prime — is described as a company dedicated to rare diseases. PIK3CA gain-of-function mutations drive not only common cancers but also a spectrum of rare overgrowth conditions known as PIK3CA-related overgrowth spectrum disorders, where targeted PI3Kα inhibition has shown biological rationale. Industry and transaction context The LAE118 license agreement arrives in the middle of a concentrated wave of large-pharma and venture capital activity targeting next-generation PI3Kα mutant-selective inhibitors. In March 2026, Novartis agreed to acquire Synnovation Therapeutics’ pan-mutant selective PI3Kα program SNV4818 for up to USD 3 billion, paying USD 2 billion upfront — a transaction that set a high-water mark for the class. The competitive field for pan-mutant selective PI3Kα inhibitors has become notably crowded. Relay Therapeutics’ zovegalisib (RLY-2608), an allosteric pan-mutant isoform-selective inhibitor, is in a Phase III pivotal study in HR+/HER2- breast cancer. Eli Lilly’s tersolisib (STX-478), acquired via Scorpion Therapeutics, has entered a front-line pivotal trial. Celcuity’s gedatolisib, a pan-PI3K/mTOR inhibitor, met the primary endpoint of the Phase III VIKTORIA-1 trial against alpelisib in PIK3CA-mutant breast cancer. LAE118 enters this landscape without clinical efficacy data and with multiple competitors already generating late-stage readouts. The structural features of the Laekna Vasque Bio partnership are worth examining in the context of how Chinese biotech companies have been structuring ex-China deals. The 50% strategic transaction participation right — entitling Laekna to half the value of any qualifying M\&A or sublicense involving LAE118 — goes beyond standard royalty and milestone protections. It functions more like a co-ownership clause than a typical licensor protection, and reflects a pattern seen in other recent China-to-Western deals where originators have sought to retain economic exposure beyond conventional milestone structures. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/ Leave a Reply Cancel reply Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Privacy Terms About Us Copyright © 2026. AllSci Corp. All rights reserved.

CAMBRIDGE, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in two upcoming fireside chats in June: 2026 Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 12:45 p.m. ET Goldman Sachs 47 th Annual Global Healthcare Conference on Monday, June 8, 2026 at 8:40 a.m. ET The fireside chats will be webcast live and may be accessed through Relay Therapeutics’ website under Events in the News & Events section through the following link: . An archived replay of the webcast will be available for up to 30 days following the event. About Relay Therapeutics Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. Relay Therapeutics’ Dynamo® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The company’s lead clinical asset, zovegalisib, is the first pan-mutant selective PI3Kα inhibitor to enter clinical development and is currently in a Phase 3 clinical trial (ReDiscover-2) in HR+/HER2- metastatic breast cancer. Zovegalisib is also being investigated in a group of genetic disease indications called PI3Kα-driven vascular anomalies. Relay Therapeutics’ pipeline also includes programs for NRAS-driven solid tumors and Fabry disease. For more information, please visit or follow us on LinkedIn . Contact: Mitch Maisel mmaisel@relaytx.com Media: Dan Budwick 1AB 973-271-6085 dan@1abmedia.com